- Patent Title: Cancer therapy targeting intercellular adhesion molecule 4 (ICAM4)
-
Application No.: US15532844Application Date: 2015-12-02
-
Publication No.: US10550186B2Publication Date: 2020-02-04
- Inventor: Vikas P. Sukhatme , Zaheed Husain
- Applicant: Beth Israel Deaconess Medical Center, Inc.
- Applicant Address: US MA Boston
- Assignee: Beth Israel Deaconess Medical Center, Inc.
- Current Assignee: Beth Israel Deaconess Medical Center, Inc.
- Current Assignee Address: US MA Boston
- Agency: Fish & Richardson P.C.
- International Application: PCT/US2015/063347 WO 20151202
- International Announcement: WO2016/089950 WO 20160609
- Main IPC: A61K41/00
- IPC: A61K41/00 ; A61K51/00 ; G01N33/53 ; C07K16/28 ; G01N33/574 ; A61K39/395 ; A61K47/68 ; A61K45/06 ; C07K16/30 ; G01N33/569

Abstract:
Methods for treating cancer, e.g., in conjunction with anti-cancer therapy, like immunotherapy, and for identifying candidate therapeutic agents, by targeting ICAM4. While MDSCs in mice have been extensively characterized, their human counterparts are not well defined, and cell markers present in mice are not always usable in humans. MDSCs have been described as a heterogenous population of myeloid derived cells with immune suppressive capacity (5, 9, 40, 41). Recent renewed interest in the role of MDSC accumulation in human tumors has resulted in the increased need to define these cells better in order to target them for therapeutic intervention.
Public/Granted literature
- US20170362320A1 CANCER THERAPY TARGETING INTERCELLULAR ADHESION MOLECULE 4 (ICAM4) Public/Granted day:2017-12-21
Information query